Oruka Therapeutics annual total debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Total Debt Growth & History (ORKA)
Oruka Therapeutics's total debt was $1.9M for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.9M | $964,000 | +99.59% |
| 2024 | 2024-12-31 | $968,000 | $688,000 | +245.71% |
| 2023 | 2023-12-31 | $280,000 | −$103,000 | −26.89% |
| 2022 | 2022-12-31 | $383,000 | −$100,000 | −20.70% |
| 2021 | 2021-12-31 | $483,000 | $33,000 | +7.33% |
| 2020 | 2020-12-31 | $450,000 | $450,000 | — |
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | $0 | — |
| 2017 | 2017-12-31 | $0 | $0 | — |
| 2016 | 2016-12-31 | $0 | $0 | — |
| 2015 | 2015-12-31 | $0 | — | — |
Oruka Therapeutics quarterly total debt
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | $220,000 | +9.46% |
| Q1 2026 | 2026-03-31 | $1.8M | $860,000 | +90.81% |
| Q4 2025 | 2025-12-31 | $1.9M | $964,000 | +99.59% |
| Q3 2025 | 2025-09-30 | $1.9M | $924,000 | +93.52% |
| Q2 2025 | 2025-06-30 | $2.3M | $2.3M | +9591.67% |
| Q1 2025 | 2025-03-31 | $947,000 | $899,000 | +1872.92% |
| Q4 2024 | 2024-12-31 | $968,000 | $688,000 | +245.71% |
| Q3 2024 | 2024-09-30 | $988,000 | $687,000 | +228.24% |
| Q2 2024 | 2024-06-30 | $24,000 | −$305,000 | −92.71% |
| Q1 2024 | 2024-03-31 | $48,000 | −$309,000 | −86.55% |
| Q4 2023 | 2023-12-31 | $280,000 | −$103,000 | −26.89% |
| Q3 2023 | 2023-09-30 | $301,000 | −$108,000 | −26.41% |
| Q2 2023 | 2023-06-30 | $329,000 | −$106,000 | −24.37% |
| Q1 2023 | 2023-03-31 | $357,000 | −$103,000 | −22.39% |
| Q4 2022 | 2022-12-31 | $383,000 | −$100,000 | −20.70% |
| Q3 2022 | 2022-09-30 | $409,000 | −$98,000 | −19.33% |
| Q2 2022 | 2022-06-30 | $435,000 | −$87,000 | −16.67% |
| Q1 2022 | 2022-03-31 | $460,000 | $10,000 | +2.22% |
| Q4 2021 | 2021-12-31 | $483,000 | $33,000 | +7.33% |
| Q3 2021 | 2021-09-30 | $507,000 | $507,000 | — |
| Q2 2021 | 2021-06-30 | $522,000 | $522,000 | — |
| Q1 2021 | 2021-03-31 | $450,000 | $450,000 | — |
| Q4 2020 | 2020-12-31 | $450,000 | $450,000 | — |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q2 2020 | 2020-06-30 | $0 | $0 | — |
| Q1 2020 | 2020-03-31 | $0 | $0 | — |
| Q4 2019 | 2019-12-31 | $0 | $0 | — |
| Q3 2019 | 2019-09-30 | $0 | $0 | — |
| Q2 2019 | 2019-06-30 | $0 | $0 | — |
| Q1 2019 | 2019-03-31 | $0 | $0 | — |
| Q4 2018 | 2018-12-31 | $0 | $0 | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | $0 | $0 | — |
| Q4 2017 | 2017-12-31 | $0 | $0 | — |
| Q3 2017 | 2017-09-30 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $0 | $0 | — |
| Q1 2017 | 2017-03-31 | $0 | $0 | — |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
| Q2 2016 | 2016-06-30 | $0 | — | — |
| Q1 2016 | 2016-03-31 | $0 | — | — |
| Q4 2015 | 2015-12-31 | $0 | — | — |
Oruka Therapeutics total debt trends
Over the last five fiscal years, Oruka Therapeutics's total debt increased from $450,000 to $1.9M, a change of $1.5M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
